Search Results for "Alnylam"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Patisiran Treatment for ATTR Cardiac Amyloidosis: 18-Month Results of the Phase 3 APOLLO-B Study

Patisiran: Transitioning from Inotersen

Standard response letter on transitioning from an antisense oligonucleotide to patisiran.

Vutrisiran: Cross-Reactivity with Patisiran

Standard response letter on the cross-reactivity between vutrisiran and patisiran.

Zilebesiran: KARDIA-2 Study

Standard response letter on zilebesiran and the KARDIA-2 study, a phase 2 study evaluating the efficacy and safety of zilebesiran as add-on therapy in patients with hypertension not adequately controlled by a standard-of-care antihypertensive medication including diuretic (indapamide), CCB (amlodipine), or ARB (olmesartan).

Givosiran: Post-Dose Monitoring

Standard response letter on givosiran and monitoring post-injection.

Vutrisiran: Survival and Mortality

Standard response letter on mortality and survival data from the HELIOS studies of vutrisiran.

Patient Demographics and clinical characteristics at enrolment in ELEVATE, an international registry of Acute Hepatic Porphyria

Patisiran: Dosing Schedule

Standard response letter on patisiran and the dosing schedule used in clinical trials.

HELIOS A: Study of Vutrisiran in Patients with hATTR Amyloidosis

Lumasiran: Clinical Pharmacology

Standard Response Letter on lumasiran and its pharmacokinetic and pharmacodynamic properties.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.